Literature DB >> 30916628

Association of Muscle Mass with Survival after Radical Prostatectomy in Patients with Prostate Cancer.

Sahyun Pak1, Seo Young Park2, Teak Jun Shin3, Dalsan You4, In Gab Jeong4, Jun Hyuk Hong4, Choung-Soo Kim4, Hanjong Ahn4.   

Abstract

PURPOSE: Although muscle mass has been associated with survival in patients with various types of solid tumors, the relationship between muscle mass and survival in patients with prostate cancer remains unclear. We retrospectively investigated the association of muscle mass with survival after radical prostatectomy in patients with prostate cancer.
MATERIALS AND METHODS: We reviewed the records of 2,042 patients who underwent radical prostatectomy of prostate cancer between 1998 and 2013. Muscle mass was evaluated by measuring the psoas muscle index on preoperative computerized tomography images.
RESULTS: In the lowest, second, third and highest psoas muscle index quartiles the 10-year distant metastasis-free survival rate was 72.5%, 83.8%, 92.3% and 93.7% (p <0.001), the 10-year cancer specific survival rate was 85.7%, 92.1%, 96.8% and 97.6%, and the 10-year overall survival rate was 74.5%, 79.6%, 89.8% and 90.6%, respectively (each p <0.001). The psoas muscle index positively correlated with the body mass index, serum concentrations of IGFBP-3 and bioavailable testosterone, and inversely correlated with patient age, the serum SHBG concentration and the neutrophil-to-lymphocyte ratio. On multivariable analysis the psoas muscle index was independently associated with increased risks of biochemical recurrence, distant metastasis, and cancer specific and overall death.
CONCLUSIONS: Low muscle mass may be associated with increased risks of recurrence and mortality in patients who undergo radical prostatectomy of prostate cancer regardless of the body mass index. Large-scale prospective studies are warranted.

Entities:  

Keywords:  body composition; prostatectomy; prostatic neoplasms; survival analysis

Mesh:

Year:  2019        PMID: 30916628     DOI: 10.1097/JU.0000000000000249

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Nexrutine® preserves muscle mass similar to exercise in prostate cancer mouse model.

Authors:  Darpan I Patel; Derek Wallace; Kira Abuchowski; Paul Rivas; Amber Gallegos; Nicolas Musi; Addanki Pratap Kumar
Journal:  Physiol Rep       Date:  2019-08

2.  Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer.

Authors:  Sahyun Pak; Myeong Seong Kim; Eun Young Park; Sung Han Kim; Kang Hyun Lee; Jae Young Joung
Journal:  Front Oncol       Date:  2020-04-17       Impact factor: 6.244

Review 3.  Pathophysiological mechanisms explaining poor clinical outcome of older cancer patients with low skeletal muscle mass.

Authors:  Stéphanie M L M Looijaard; Miriam L Te Lintel Hekkert; Rob C I Wüst; René H J Otten; Carel G M Meskers; Andrea B Maier
Journal:  Acta Physiol (Oxf)       Date:  2020-07-24       Impact factor: 6.311

4.  CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.

Authors:  Sara Sheikhbahaei; Diane K Reyes; Steven P Rowe; Kenneth J Pienta
Journal:  Prostate       Date:  2020-12-01       Impact factor: 4.104

5.  Body Composition Analysis of 10 Years versus 5 Years of Adjuvant Endocrine Therapy in Patients with Nonmetastatic Breast Cancer.

Authors:  Ruyi Hu; Xinran Cheng; Jun Liu; Xu Lai; Ruifeng Wang; Dongchang Yu; Yanan Fan; Zhaoshi Yu
Journal:  J Oncol       Date:  2021-01-16       Impact factor: 4.375

Review 6.  Does Androgen Deprivation for Prostate Cancer Affect Normal Adaptation to Resistance Exercise?

Authors:  Tormod S Nilsen; Sara Hassing Johansen; Lene Thorsen; Ciaran M Fairman; Torbjørn Wisløff; Truls Raastad
Journal:  Int J Environ Res Public Health       Date:  2022-03-23       Impact factor: 3.390

7.  Body composition and pelvic fat distribution are associated with prostate cancer aggressiveness and can predict biochemical recurrence.

Authors:  Yu-Hsuan Chien; Ming-Li Hsieh; Ting-Wen Sheng; Ying-Hsu Chang; Li-Jen Wang; Cheng-Keng Chuang; See-Tong Pang; Chun-Te Wu; I-Hung Shao
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

8.  Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Ji Hyun Lee; Byul A Jee; Jae-Hun Kim; Hoyoung Bae; Jae Hoon Chung; Wan Song; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Se Hoon Park; Minyong Kang
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.